Eli Lilly and Co
FTC sues drug middlemen for allegedly inflating insulin prices
The Federal Trade Commission on Friday sued three large U.S. health companies that negotiate insulin prices, arguing the drug middlemen use practices that boost their profits while “artificially” inflating costs for patients. The suit targets the three biggest so-called pharmacy benefit managers, UnitedHealth Group’s Optum Rx, CVS Health’s Caremark and Cigna’s Express Scripts. All are […]
Read More
Novartis not joining the ‘frenzy’ of weight loss drugs, CEO says
The CEO of Novartis said Wednesday that the Swiss pharmaceutical giant does not plan to enter into the “frenzy” of weight loss drugs, preferring instead to focus on areas where it can build a “unique position.” Speaking to CNBC, Vas Narasimhan said that the company was researching treatments that deal with the secondary effects of […]
Read More
Healthy Returns: How competitive can Roche be in the weight loss drug market?
Headquarters of Roche, multinational pharmaceutical industry on December 27, 2021 in Madrid, Spain. Cristina Arias | Cover | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Good afternoon! Roche is one of several drugmakers […]
Read More
Drugmakers bet billions that targeted radiation could become the next cancer breakthrough
Drugmakers are betting that delivering radiation directly to tumors will become the next big cancer breakthrough. Bristol Myers Squibb, AstraZeneca, Eli Lilly and other pharmaceutical companies have spent some $10 billion on deals to acquire or work with radiopharmaceuticals makers. They’ve snapped up smaller upstarts to get their hands on technology that, while in its […]
Read More
Eli Lilly to invest $1.8 billion to expand manufacturing for weight loss, diabetes and Alzheimer’s drugs
A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Eli Lilly on Thursday said it will invest $1.8 billion to boost manufacturing for its newly approved Alzheimer’s drug and highly popular weight loss and diabetes treatments, among other medicines, […]
Read More
Healthy Returns: More than 50 million privately insured adults could be eligible for GLP-1 drugs
Weight loss syringes of the brands “Wegovy”, “Ozempic” and “Mounjaro” are sold at In der Achat Apotheke in Mitte, Germany. Picture Alliance | Picture Alliance | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future […]
Read More
Eli Lilly names insider Lucas Montarce as new finance chief
An Eli Lilly and Company pharmaceutical manufacturing plant is pictured in Branchburg, New Jersey, on March 5, 2021. Mike Segar | Reuters U.S. drugmaker Eli Lilly on Monday said it appointed insider Lucas Montarce as its new chief financial officer, effective immediately. Montarce, who joined Lilly in 2001, has held various finance leadership roles within […]
Read More
Wells Fargo’s top picks in September include this tech giant and pharma leader
Wells Fargo highlighted a slate of stocks for September that are poised for major upside. CNBC Pro combed through the firm’s research for overweight-rated stocks that analysts believe have even more room to run. They include Uber Technologies, Microsoft, Burlington Stores, D.R. Horton and Eli Lilly. Burlington Stores “Momentum is building,” analyst Ike Boruchow said […]
Read More
Healthy Returns: Eli Lilly could soon become the first $1 trillion health-care stock
A sign with the company logo outside the headquarters of Eli Lilly and Company in Indianapolis, Indiana, March 17, 2024. Scott Olson | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Earlier this […]
Read More
We’re taking a nearly 300% profit on a hot drug stock — adhering to an investing rule to live by
Shortly after the opening bell, we’ll be selling 10 shares of Eli Lilly at roughly $958 each. Following Monday’s trade, Jim Cramer’s Charitable Trust will own 100 shares of LLY, decreasing its weighting to 2.85% from about 3.13%. Now that we are no longer restricted, we are selling some Eli Lilly shares. We downgraded Lilly […]
Read More